Cell Signaling and Signal Transduction

Fundamentals of Intercellular Communication and Signaling Ranges

• Core Principles of Cell Signaling:
  • Communication Mechanism: Intercellular signaling coordinates biological functions across tissues and organ systems. A sending cell synthesizes and secretes chemical ligands into the extracellular milieu. Target cells express stereospecific transmembrane or intracellular receptors that bind these ligands, triggering intracellular biochemical cascades culminating in specialized cellular responses.
  • Cellular Specificity: Cells that lack the cognate receptor for a specific signaling molecule ($\emptyset$) remain unresponsive, defining the target versus non-target cell paradigm.
  • Signal Diversity and Cellular Divergence: Cells detect diverse inputs including peptides, small amino acid derivatives, lipids, dissolved gases, and physical stimuli (such as photons of light or mechanical force). Furthermore, identical signaling molecules can trigger distinct, cell-type-specific responses depending on the intracellular complement of downstream effectors and transcription factors.
  • Necessity of Signal Termination: Inactivating signals is as critical as initiating them. Failure to turn off a pathway prevents the cell from clearing its receptors to detect subsequent signals and can cause continuous, pathological responses (such as unregulated cell division leading to neoplasia).

• Spatial Classification of Intercellular Signaling:
  • Autocrine Signaling: The signaling cell releases ligands that bind to cognate receptors expressed on its own plasma membrane, directly modulating its own state (e.g., self-stimulation during immune activation or autonomous tumor cell proliferation).
  • Paracrine Signaling: Short-range communication in which secreted signaling molecules diffuse locally through the extracellular matrix to act exclusively on nearby target cells. Notable examples include neurotransmitters traversing synaptic clefts and localized growth factors regulating adjacent tissue cells.
  • Endocrine Signaling: Long-range signaling mediated by hormones. Specialized endocrine cells secrete hormones directly into the circulatory bloodstream, allowing systemic transport across the body to reach distant target tissues displaying matching high-affinity receptors.

• Representative Receptors and Ligand Classes:
  • Rhodopsin: A photosensitive receptor in the retina that uses the light-absorbing chromophore $11\text{-}cis\text{-retinal}$ to detect photons and initiate visual excitation.
  • Soluble Guanylate Cyclase ((\alpha)-3 subunit): An intracellular receptor/enzyme activated by the gas nitric oxide ($\text{NO}$), producing cyclic GMP ($\text{cGMP}$).
  • Olfactory Receptor (Family 2, Subfamily J, Member 3): A specialized sensory receptor dedicated to detecting volatile airborne odorants.
  • Prostaglandin E Receptor 2 (EP2 Subtype): A lipid-activated receptor that binds eicosanoid ligands such as prostaglandin $\text{E}_2$.
  • Metabotropic Glutamate Receptor 1 (mGluR1): A G-protein-coupled receptor that responds to the amino acid neurotransmitter L-glutamate.
  • Epidermal Growth Factor Receptor (EGFR): A receptor tyrosine kinase that binds polypeptide growth factors to stimulate cell proliferation and survival.

Mechanisms of Signal Transduction and Post-Translational Modification

• Signal Transduction Architecture:
  • Definition: The molecular process whereby an extracellular first messenger binds to a cell-surface receptor, initiating an internal biochemical cascade that produces a functional cellular outcome.
  • Sequential Relay (The Molecular Rube Goldberg Machine): Upstream molecular changes sequentially cause conformational, catalytic, or localization shifts in downstream intermediates.
  • General Pathway Stages:
  1. An extracellular signaling molecule (first messenger) binds specifically to the extracellular domain of a transmembrane receptor.
  2. The receptor undergoes a conformational change across the phospholipid bilayer.
  3. The intracellular receptor domain activates an effector enzyme or recruits transducer proteins.
  4. Effector enzymes generate low-molecular-weight second messengers (e.g., $\text{cAMP}$, $\text{cGMP}$, $\text{IP}_3$, $\text{DAG}$) or modify membrane lipids.
  5. Second messengers diffuse throughout the cytosol, allosterically activating target kinases or ion channels.
  6. Kinases phosphorylate downstream target proteins, altering enzymatic activities or protein-protein interactions.
  7. End-stage cellular responses are enacted: transcriptional reprogramming, cell survival, protein synthesis, cytoskeletal movement, apoptosis (cell death), or metabolic adjustments.

• Enzymatic Regulation via Kinases and Phosphatases:
  • Protein Kinases: Catalyze the transfer of the terminal gamma-phosphate group ($\text{PO}_4^{3-}$) from $\text{ATP}$ to specific amino acid side-chain hydroxyl groups on target proteins. Target residues primarily include:
  • Serine (Ser): Forming phosphoserine.
  • Threonine (Thr): Forming phosphothreonine.
  • Tyrosine (Tyr): Forming phosphotyrosine.
  • Histidine (His): Forming phosphohistidine (less common, occurs at nitrogen positions such as N3).
  • Lipid Kinases: Transfer phosphate groups to polar headgroups of membrane phospholipids, modifying membrane recruitment sites. For example, Phosphatidylinositol ($\text{PI}$) is converted via sequential phosphorylation steps:
  1. $\text{PI} \xrightarrow{\text{PI 4-kinase}} \text{PI(4)P}$
  2. $\text{PI(4)P} \xrightarrow{\text{PIP 5-kinase}} \text{PI(4,5)P}_2$
  • Phosphatases: Hydrolytically remove phosphate groups ($\text{P}_i$) from phosphorylated proteins and lipids, returning them to their unphosphorylated basal state and reversing kinase action.

G-Protein-Coupled Receptors (GPCRs) and Heterotrimeric G-Protein Activation

• Structural Organization of GPCRs:
  • 7-Transmembrane (7TM) Architecture: GPCRs feature an extracellular amino ($\text{N}$-) terminus, seven transmembrane $\alpha$-helices ($\text{TM-I}$ through $\text{TM-VII}$) traversing the plasma membrane, three extracellular connecting loops, three intracellular loops, and an intracellular carboxyl ($\text{C}$-) terminus.
  • Ligand Binding and Activation: Extracellular loops and transmembrane pockets coordinate ligand binding. Ligand binding triggers a concerted structural rearrangement, specifically an outward movement of transmembrane helix 6 ($\text{TM-VI}$), exposing intracellular binding sites for heterotrimeric G proteins.

• The Heterotrimeric G-Protein Cycle:
  • Subunit Composition: Consists of three distinct polypeptides: $\text{G}\alpha$, $\text{G}\beta$, and $\text{G}\gamma$. Both $\text{G}\alpha$ and $\text{G}\gamma$ are anchored to the plasma membrane inner leaflet by lipid anchors.
  • Inactive Basal State:
  • The GPCR is unoccupied by ligand.
  • The $\text{G}\alpha$ subunit is bound to Guanosine Diphosphate ($\text{GDP}$).
  • In this $\text{GDP}$-bound conformation, $\text{G}\alpha$ associates tightly with the $\text{G}\beta\gamma$ heterodimer, forming an inactive heterotrimer that remains uncoupled from the receptor or effectors.
  • Step-by-Step Activation:
  1. Ligand Binding: Extracellular agonist binding induces an active conformation in the GPCR.
  2. Receptor-G Protein Association: The active receptor binds the heterotrimeric G protein complex.
  3. Guanine Nucleotide Exchange: The receptor functions as a Guanine Nucleotide Exchange Factor (GEF), inducing $\text{G}\alpha$ to release bound $\text{GDP}$ and bind Guanosine Triphosphate ($\text{GTP}$).
  4. Subunit Dissociation: $\text{GTP}$ binding triggers a conformational shift in the switch regions of $\text{G}\alpha$, decreasing its affinity for both the GPCR and the $\text{G}\beta\gamma$ complex. The $\text{G}\alpha\text{-GTP}$ monomer dissociates from the $\text{G}\beta\gamma$ dimer.
  5. Effector Regulation: Free $\text{G}\alpha\text{-GTP}$ and free $\text{G}\beta\gamma$ laterally diffuse along the inner membrane face to interact directly with specific membrane-bound effectors (enzymes or ion channels), initiating downstream signal transduction cascades.

• Representative GPCR Physiological Systems:
  • Epinephrine / $\beta$-Adrenergic Receptor: Activates adenylyl cyclase; stimulates glycogen breakdown.
  • Serotonin / Serotonin Receptor: Activates adenylyl cyclase; mediates behavioral sensitization and learning in Aplysia.
  • Light / Rhodopsin: Activates cGMP phosphodiesterase; leads to visual excitation in photoreceptors.
  • IgE–Antigen Complexes / Mast Cell IgE Receptor: Activates phospholipase C; stimulates immune mediator secretion.
  • f-Met Peptide / Chemotactic Receptor: Activates phospholipase C; drives leukocyte chemotaxis toward bacterial peptides.
  • Acetylcholine / Muscarinic Receptor: Couples to potassium channels; slows cardiac pacemaker activity.

The Epinephrine Cascade in the Liver: Glycogenolysis, Amplification, and Gene Regulation

• Physiological Goal in Hepatocytes:
  • Fight-or-Flight Metabolic Response: During acute stress, epinephrine is released from the adrenal medulla into circulation to mobilize glucose into the bloodstream, supplying energy ($\text{ATP}$) to working skeletal muscle and the central nervous system.
  • Dual Reciprocal Control via Phosphorylation:
  • Glycogen Phosphorylase: Activated by phosphorylation, accelerating glycogen breakdown into glucose.
  • Glycogen Synthase: Inactivated by phosphorylation, halting the conversion of glucose into stored glycogen and preventing an unproductive futile cycle.

• Adenylyl Cyclase and Second Messenger Synthesis:
  • Enzyme Structure: Adenylyl cyclase is a multipass transmembrane enzyme containing 12 transmembrane helices organized into two bundles of six, connected to two catalytic cytoplasmic domains that form the active site.
  • Cyclic AMP Synthesis: Upon activation by $\text{G}_{\alpha s}\text{-GTP}$, adenylyl cyclase catalyzes the cyclization of $\text{ATP}$ into the soluble second messenger cyclic Adenosine Monophosphate ($\text{cAMP}$), releasing inorganic pyrophosphate ($\text{PP}_i$):     $\text{ATP} \xrightarrow{\text{Adenylyl Cyclase}} \text{cAMP} + \text{PP}_i$
  • Spatial Diffusion of $\text{cAMP}$: As a small, water-soluble molecule, $\text{cAMP}$ diffuses rapidly away from the plasma membrane throughout the cytoplasm. Visualized in sensory neurons stimulated with $50\,\mu\text{M}$ serotonin ($\text{5-HT}$), intracellular $\text{cAMP}$ levels rise noticeably by $19\,\text{s}$, reach widespread saturation across a $120\,\mu\text{m}$ field by $109\,\text{s}$, and remain elevated before returning toward baseline after $10\,\text{min}$.

• Complete Step-by-Step Epinephrine Cascade in Hepatocytes:
  1. Receptor Activation: Epinephrine binds the extracellular pocket of a hepatic $\beta$-adrenergic GPCR.
  2. G-Protein Activation: The receptor activates the stimulatory heterotrimeric G protein; $\text{G}_{\alpha s}$ exchanges $\text{GDP}$ for $\text{GTP}$.
  3. Adenylyl Cyclase Stimulation: $\text{G}_{\alpha s}\text{-GTP}$ binds and activates the effector enzyme adenylyl cyclase.
  4. Second Messenger Generation: Active adenylyl cyclase rapidly converts cytosolic $\text{ATP}$ to $\text{cAMP}$.
  5. Protein Kinase A (PKA) Activation: $\text{cAMP}$ binds allosterically to the regulatory subunits of inactive PKA, releasing its active catalytic subunits.
  6. Inhibition of Glycogen Synthesis: Active PKA phosphorylates Glycogen Synthase, converting it to an inactive form ($\text{Glycogen Synthase-P}$) to block glycogen construction.
  7. Activation of Kinase Cascade: Active PKA phosphorylates and activates Phosphorylase Kinase ($\text{Phosphorylase Kinase-P}$).
  8. Activation of Glycogen Phosphorylase: Active Phosphorylase Kinase phosphorylates inactive Glycogen Phosphorylase, converting it into active Glycogen Phosphorylase ($\text{Glycogen Phosphorylase-P}$).
  9. Glycogenolysis: Active Glycogen Phosphorylase cleaves terminal $\alpha(1\rightarrow 4)$ glycosidic bonds from glycogen using inorganic phosphate, producing Glucose 1-phosphate.
  10. Glucose Secretion: Phosphoglucomutase converts Glucose 1-phosphate to Glucose 6-phosphate, which is converted to free Glucose by glucose 6-phosphatase. Free glucose is transported across the plasma membrane into the bloodstream via facilitative glucose transporters.
  11. Transcriptional Activation: Free catalytic subunits of PKA can also translocate into the nucleus and phosphorylate the transcription factor CREB (cAMP Response Element-Binding protein). Phosphorylated CREB dimerizes and binds to cAMP Response Elements (CRE) on genomic DNA, driving the expression of gluconeogenic and metabolic genes.
• Signal Amplification:
  • Multi-tiered cascades allow a minimal initial stimulus to yield a large functional output. Binding of a single epinephrine molecule to its receptor activates multiple $\text{G}_{\alpha s}$ proteins. Each adenylyl cyclase produces thousands of $\text{cAMP}$ molecules, and downstream catalytic activation continues at each kinase tier, resulting in the rapid generation and release of millions of glucose molecules into the circulation.

Termination and Downregulation of GPCR Signaling

• Fast Inactivation Mechanisms:
  • Intrinsic GTPase Hydrolysis: $\text{G}\alpha$ possesses intrinsic GTPase activity that hydrolyzes its bound $\text{GTP}$ to $\text{GDP}$ and inorganic phosphate ($\text{P}_i$):     $\text{G}\alpha\text{-GTP} \rightarrow \text{G}\alpha\text{-GDP} + \text{P}_i$
  • Heterotrimer Reassembly: In its $\text{GDP}$-bound form, $\text{G}\alpha\text{-GDP}$ dissociates from the effector enzyme and reassembles with the $\text{G}\beta\gamma$ heterodimer into the inactive ground state.
  • GPCR Kinase (GRK) Phosphorylation: G protein-coupled receptor kinases (GRKs) specifically phosphorylate serine and threonine residues located on the intracellular loops and carboxyl-terminal tail of the ligand-activated receptor.
  • Arrestin Binding: Phosphorylated GPCRs recruit the cytoplasmic capping protein Arrestin. Arrestin binding sterically blocks the intracellular interface, preventing any further coupling to heterotrimeric G proteins even when the extracellular ligand remains bound.
  • Second Messenger Degradation: Cytosolic Phosphodiesterase hydrolyzes $\text{cAMP}$ to inactive adenosine monophosphate ($\text{AMP}$), halting further PKA activation:     $\text{cAMP} + \text{H}_2\text{O} \xrightarrow{\text{Phosphodiesterase}} \text{AMP}$
  • Protein Dephosphorylation: Serine/threonine phosphatases remove phosphate groups from Glycogen Synthase (reactivating it), Phosphorylase Kinase (inactivating it), and Glycogen Phosphorylase (inactivating it).

• Slow Inactivation via Receptor-Mediated Endocytosis:
  • Clathrin Coat Recruitment: Receptor-bound arrestin acts as an adapter, binding to clathrin and the AP2 adaptor complex to initiate coated-pit assembly.
  • Internalization: Clathrin-coated vesicles bud off and pinch away from the plasma membrane, transporting the internalized GPCRs to endosomes.
  • Three Alternative Intracellular Fates:
  1. Alternative Pathway Signaling: Endosomal GPCR-arrestin complexes can act as scaffolding hubs that drive distinct, non-G-protein signaling cascades (such as initiating the ERK/MAPK pathway).
  2. Lysosomal Destruction: Receptors can be sorted from endosomes to lysosomes, where acid hydrolases degrade the receptor protein, causing long-term desensitization (receptor downregulation).
  3. Receptor Recycling: In the acidic lumen of the endosome, the ligand dissociates, phosphatases dephosphorylate the receptor, arrestin detaches, and the resensitized receptor is returned via recycling endosomes to the plasma membrane.

GPCR Pathology and Disease Pathophysiology

• Diseases Linked to Defective G Proteins:

  • Albright's Hereditary Osteodystrophy and Pseudohypoparathyroidism: Caused by loss-of-function mutations in $\text{G}_{s\alpha}$, impairing downstream endocrine responses to parathyroid hormone.
  • McCune–Albright Syndrome: Caused by postzygotic somatic activating mutations in $\text{G}_{s\alpha}$, causing autonomous, ligand-independent adenylyl cyclase activation and mosaic endocrine hyperfunction.
  • Pituitary and Thyroid Tumors (gsp Oncogene): Activating somatic point mutations in $\text{G}_{s\alpha}$ that disrupt intrinsic GTPase activity, locking $\text{G}_{s\alpha}$ in a continuously active state to drive autonomous cell proliferation.
  • Adrenocortical and Ovarian Tumors (gip Oncogene): Arise from oncogenic activating mutations in $\text{G}_{i\alpha}$.
  • Combined Precocious Puberty and Pseudohypoparathyroidism: Associated with specific temperature-sensitive mutations in $\text{G}_{s\alpha}$.

• Diseases Linked to Defective G-Protein-Coupled Receptors:

  • Familial Hypocalciuric Hypercalcemia: Mutations in the calcium-sensing receptor (human analogue of BoPCAR1 receptor).
  • Neonatal Severe Hyperparathyroidism: Homozygous inactivating mutations in the calcium-sensing receptor (human analogue of BoPCAR1 receptor).
  • Hyperthyroidism (Thyroid Adenomas): Constitutively active thyrotropin (TSH) receptors driving continuous thyroid hormone synthesis.
  • Familial Male Precocious Puberty: Activating mutations in the luteinizing hormone (LH) receptor.
  • X-Linked Nephrogenic Diabetes Insipidus: Loss-of-function mutations in the renal V2 vasopressin receptor, preventing water reabsorption.
  • Retinitis Pigmentosa: Inherited mutations in the rhodopsin receptor.
  • Color Blindness and Spectral Sensitivity Variations: Mutations in cone opsin GPCR genes (red, green, and blue cone photoreceptors).
  • Familial Glucocorticoid Deficiency: Mutations in the adrenocorticotropic hormone (ACTH) receptor.
  • Short Stature and Obesity: Loss-of-function mutations in the ghrelin receptor.
  • Early-Onset Severe Obesity: Heterozygous inactivating mutations in the melanocortin-4 receptor (MC4R).
  • Decreased Fertility: Inactivating mutations in the follicle-stimulating hormone (FSH) receptor.

• Molecular Case Study: Retinitis Pigmentosa:

  • Clinical Manifestation: A degenerative retinal dystrophy characterized by night blindness, progressive loss of peripheral visual fields (tunnel vision), and eventual blindness.
  • Wild-Type Rhodopsin Structure: Consists of seven transmembrane domains in the disc membranes of rod cells. The visual chromophore $11\text{-}cis\text{-retinal}$ is covalently attached via a protonated Schiff base to Lysine 296 ($\text{K296}$), stabilized by a counterion salt bridge with Glutamate 113 ($\text{E113}$).
  • Pathogenic Mutation Classes in Rhodopsin:
  • $\text{T17M}$ and $\text{P23H}$ Mutations (N-terminal / Intradiscal Domain): Cause severe protein misfolding, triggering the Unfolded Protein Response (UPR), Caspase-1 activation, reactive oxygen species (ROS) production, and membrane destruction. This disrupts intracellular $\text{Ca}^{2+}$ homeostasis, activating calpain and caspase-12 to trigger photoreceptor apoptosis.
  • $\text{G90D}$ Mutation (Transmembrane Helix II): Introduces a charged aspartate that destabilizes the salt bridge between $\text{E113}$ and $\text{K296}$. This causes constitutive, light-independent activation of the receptor, driving continuous transducin-dependent and independent signaling that leads to retinal degeneration.
  • $\text{Q344Ter}$ Mutation (Carboxyl-Terminal Cytoplasmic Tail): Truncates the cytoplasmic targeting sequence, disrupting outer segment trafficking and causing mistargeted rhodopsin accumulation and cell death.

Receptor Tyrosine Kinases (RTKs) and Downstream Adapter Interactions

• RTK Architecture and Dimerization Mechanisms:
  • Structural Domains: Single-pass transmembrane proteins featuring an extracellular ligand-binding domain, a single hydrophobic transmembrane $\alpha$-helix, an intracellular juxtamembrane regulatory segment, a tyrosine kinase catalytic domain, and a carboxyl-terminal regulatory tail.
  • Ligand-Mediated Dimerization: A bivalent ligand with two distinct binding surfaces binds simultaneously to two monomeric receptors, physically cross-linking them into an active dimer.
  • Receptor-Mediated Dimerization: Binding of a monovalent ligand induces an allosteric conformational shift in the extracellular domain of the monomer, exposing an interactive dimerization loop that promotes self-association with another ligand-bound receptor.
  • Trans-Autophosphorylation: Receptor dimerization brings the cytoplasmic kinase domains into close proximity. The kinase domain of one monomer phosphorylates tyrosine residues on the activation loop and cytoplasmic tail of the partner monomer, relieving autoinhibition and generating specific phosphotyrosine ($\text{Phospho-Tyr}$) docking sites.

• Modular Phosphotyrosine Recognition Domains:

  • SH2 Domains (Src Homology 2): Conserved protein modules of approximately 100 amino acids with a binding pocket tailored for phosphotyrosine along with an adjacent pocket that recognizes the flanking carboxyl-terminal amino acid residues, providing sequence specificity.
  • PTB Domains (Phosphotyrosine-Binding): Functional modules that recognize phosphorylated tyrosines, classically within an Asn-Pro-X-Tyr ($\text{NPXY}$) consensus sequence.

• Functional Classes of Downstream Signaling Proteins:

  • Adaptor Proteins: Non-catalytic accessory proteins that act as molecular bridges. Grb2 (Growth factor receptor-bound protein 2) uses an SH2 domain to bind phosphotyrosines on active RTKs while using its flanking SH3 domains to recruit proline-rich motifs on downstream exchange factors (such as Sos).
  • Docking Proteins: Scaffolding platforms that expand signaling potential. The Insulin Receptor Substrate (IRS) binds to activated RTKs via a PTB domain. The RTK then phosphorylates multiple tyrosine residues on IRS, generating docking sites for SH2-containing enzymes including PI3K and the phosphatase Shp2.
  • Transcription Factors: Latent cytosolic transcription factors such as the STAT (Signal Transducer and Activator of Transcription) family. Monomeric STATs bind phosphorylated RTK tyrosines through SH2 domains and are directly phosphorylated by the receptor's kinase domain. Phosphorylated STATs detach, form active homodimers via reciprocal SH2-phosphotyrosine interactions, and translocate to the nucleus to induce target gene transcription.
  • Signaling Enzymes: Enzymes containing SH2 domains that are recruited directly to activated receptors, bringing them near their membrane-bound substrates. Examples include Phospholipase C-$\gamma$ ($\text{PI-PLC}\gamma$), Phosphoinositide 3-Kinase (PI3K), and the protein tyrosine phosphatase Shp2.

The RTK-Ras-MAPK Signaling Pathway and Oncogenesis

• The Core RTK-Ras-MAPK Activation Cascade:
  1. Growth Factor Binding: Polypeptide growth factors (e.g., EGF, PDGF) bind the extracellular domain of the Receptor Protein-Tyrosine Kinase (Receptor PTK).
  2. Trans-Autophosphorylation: Receptor monomers dimerize, triggering trans-autophosphorylation of tyrosine residues across their cytoplasmic tails.
  3. Grb2-Sos Recruitment: Phosphotyrosine docking sites recruit the SH2 domain of the adaptor protein Grb2. Grb2 is constitutively bound via its SH3 domains to the guanine nucleotide exchange factor Sos (Son of Sevenless).
  4. Ras Activation: Translocation of Sos to the inner face of the plasma membrane places it next to membrane-anchored, inactive Ras-GDP. Sos stimulates the exchange of $\text{GDP}$ for $\text{GTP}$, forming active Ras-GTP.
  5. Raf (MAPKKK) Activation: Active Ras-GTP recruits soluble cytoplasmic Raf (a MAP kinase kinase kinase / MAPKKK) to the plasma membrane. Membrane recruitment promotes Raf phosphorylation and catalytic activation.
  6. MEK (MAPKK) Activation: Active Raf phosphorylates and activates MEK (a MAP kinase kinase / MAPKK) on two regulatory serine residues.
  7. ERK (MAPK) Activation: Active MEK, a dual-specificity kinase, phosphorylates ERK (Extracellular signal-Regulated Kinase, a MAP kinase / MAPK) on both a threonine and a tyrosine residue within a conserved $\text{Thr-Glu-Tyr}$ motif, fully activating it.
  8. Transcription Factor Activation: Activated ERK translocates into the nucleus and phosphorylates specific transcription factors (e.g., c-Jun, c-Fos, Elk-1).
  9. Cellular Response: Phosphorylated transcription factors stimulate transcription of genes required for cell cycle progression (e.g., Cyclin D1, driving entry into S phase) and cell survival.
  10. Negative Feedback via Phosphatases: Active ERK also induces expression of MAP Kinase Phosphatase-1 (MKP-1). Newly synthesized MKP-1 dephosphorylates both the threonine and tyrosine residues on ERK ($\text{ERK-P} \rightarrow \text{ERK}$, steps 10–11), returning ERK to its inactive state and terminating the mitogenic signal.

• Growth Factor Signaling Components as Oncogenes:
  • Definition of Oncogenes: Altered forms of normal cellular proto-oncogenes that promote autonomous, malignant transformation and unregulated proliferation.
  • Mechanisms of Oncogenic Activation:
  • Constitutively Active Mutations ("Always ON"): Amino acid substitutions that lock downstream transducers in an active conformation independent of upstream signals or ligand binding.
  • Protein Overexpression: Gene amplification, enhanced transcription, or reduced degradation resulting in excess protein levels.
  • Key Oncogenic Examples within the Pathway:
  • Ras Mutations: Point mutations (most frequently at positions Glycine 12, Glycine 13, or Glutamine 61) impair intrinsic GTPase activity and block GTPase-Activating Protein (GAP) binding. As a result, Ras cannot hydrolyze bound $\text{GTP}$ to $\text{GDP}$ and remains locked in the active Ras-GTP state, continuously driving downstream proliferation. Oncogenic Ras mutations are present in approximately $30\%$ of all human malignancies.
  • Raf Mutations: Specific mutations (such as $\text{BRAF}^{\text{V600E}}$) render the Raf kinase constitutively active in the absence of upstream Ras-GTP, common in cutaneous melanoma and colorectal cancer.
  • Nuclear Transcription Factors: Overexpression or amplification of AP-1 complex components (e.g., Jun and Fos) sustains high rates of transcription for genes driving cell-cycle entry, fueling uncontrolled division.